Dev Prasad
Stock Analyst at LUCID CAPITAL MARKETS
(3.14)
# 1,102
Out of 5,182 analysts
6
Total ratings
60%
Success rate
121.39%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Dev Prasad
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ATYR aTyr Pharma | Downgrades: Neutral | $11 → $1 | $0.79 | +26.01% | 1 | Sep 15, 2025 | |
| CUE Cue Biopharma | Initiates: Buy | $120 | $12.46 | +863.47% | 1 | Aug 25, 2025 | |
| IRD Opus Genetics | Initiates: Buy | $5 | $5.00 | - | 1 | Jun 17, 2025 | |
| AVTX Avalo Therapeutics | Initiates: Buy | $24 | $12.86 | +86.63% | 1 | Dec 17, 2024 | |
| IBIO iBio, Inc. | Initiates: Buy | $6 | $1.63 | +268.10% | 1 | Dec 17, 2024 | |
| CALC CalciMedica | Initiates: Buy | $13 | $0.58 | +2,154.99% | 1 | Dec 17, 2024 |
aTyr Pharma
Sep 15, 2025
Downgrades: Neutral
Price Target: $11 → $1
Current: $0.79
Upside: +26.01%
Cue Biopharma
Aug 25, 2025
Initiates: Buy
Price Target: $120
Current: $12.46
Upside: +863.47%
Opus Genetics
Jun 17, 2025
Initiates: Buy
Price Target: $5
Current: $5.00
Upside: -
Avalo Therapeutics
Dec 17, 2024
Initiates: Buy
Price Target: $24
Current: $12.86
Upside: +86.63%
iBio, Inc.
Dec 17, 2024
Initiates: Buy
Price Target: $6
Current: $1.63
Upside: +268.10%
CalciMedica
Dec 17, 2024
Initiates: Buy
Price Target: $13
Current: $0.58
Upside: +2,154.99%